<DOC>
	<DOCNO>NCT00186186</DOCNO>
	<brief_summary>The purpose study examine safety efficacy Depakote ER bipolar depression evaluate metabolic GABA change Depakote ER administration use PET MRI/MRS brain image technique .</brief_summary>
	<brief_title>Depakote ER Bipolar Depression</brief_title>
	<detailed_description>Mood disorder important public health problem . Bipolar disorder major psychiatric disorder characterize mood cycle alternate mania depression affect approximately 1 % population . Most patient treat begin early twenty embark course mark multiple recurrence , hospitalization , encounter legal authority . These disorder inflict substantial morbidity yield important deficit occupational interpersonal function . The risk suicide mood disorder may high 10 % . Although outlook recovery acute manic depressive episode generally excellent , long-term prognosis disorder varies tremendously across patient population . The introduction lithium , anticonvulsant atypical antipsychotic significantly change outlook bipolar disorder , individual chronic treatment attain complete remission indefinite prophylaxis mood episode . However , optimum outcome may limit one-third one-half treated patient . The remain experience various combination breakthrough mood episode , include chronic mood instability , persistent depression , rapid cycling . Very little research conduct bipolar disorder , medication FDA indication treat bipolar depression . Previous study suggest Depakote promise treatment mixed depress episode bipolar disorder . This study utilize extend release formulation divalproex sodium , demonstrate increased tolerability . We propose investigate safety , tolerability efficacy Depakote ER monotherapy Bipolar I , II NOS depression , monitoring associate change brain GABA level . In addition , intend evaluate ass difference brain metabolic rate GABA level bipolar disorder patient healthy volunteer .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Bipolar I , II NOS currently suffer depression Both : female male participant study Adults 18 year old race Schizophrenia schizoaffective disorder disorder exclude discretion investigator 's discretion Substance dependence within past 3 month abuse within past 2 week prior study . Positive screen psychoactive drug , stimulant drug abuse ( exclude marijuana , long dependence abuse rule accord DSMIV ) Significant risk harm self others base history mental status exam Clinically significant unstable medical condition Unstable thyroid pathology treatment initiate alter within past 3 month Clinically significant abnormal laboratory test result , vital sign , judge investigator Women pregnant nursing , WOCBP use adequate contraception judge unreliable use contraception Subjects fail ( inefficacy adverse effect ) adequate trial Depakote ; eligible patient 's may receive Depakote within 30 day screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>